Laurus Labs is planning to focus on formulations to derive significant revenue from the segment. In this regards, the company is investing Rs 300 crore in formulations and Active Pharmaceutical Ingredients (APIs) facilities in Visakhapatnam, out of which Rs 150 crore has already been spent. The remaining will be spent before the end of the current financial year.
Last month, Laurus had received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Finished Dosage Formulations (FDF) and API manufacturing plant, Unit 2, located at Achutapuram, Vishakhapatnam.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1872.60 |
| Dr. Reddys Labs. | 1376.30 |
| Cipla | 1453.50 |
| Zydus Lifesciences | 1121.65 |
| Lupin | 2407.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: